The diseases covered by the Virus Questions network illustrate four fundamentally different ways that infectious disease imposes economic costs. Each has a dedicated deep-dive page on its respective spoke site; this page is the synthesis. For the same viruses reduced to a single number each — what one case costs, medically, societally and economy-wide — see the cost-per-case table, the economic companion to the Risk Perspective.
~$14 trillion total U.S. cost
COVID-19 is the benchmark for pandemic economic damage. U.S. real GDP contracted 3.5% in 2020 — the steepest decline since 1946, per the Bureau of Economic Analysis. Total economic and mortality costs through 2023 are estimated at ~$14 trillion, per USC Schaeffer Center research, with the far larger share driven by behavioral aversion, labor-force withdrawal, and supply-chain disruption — not by direct health-care spending.
Long COVID has since emerged as an ongoing, poorly-quantified drag on labor productivity, making COVID-19's full economic cost still an open question.
Full COVID-19 economic analysis →
$3.8B lost GDP for West Africa over 2014–15 in the World Bank's October 2014 "Low Ebola" scenario ($2.2B in 2014 + $1.6B in 2015); $32.6B under its "High Ebola" scenario; ~$53B comprehensive burden per Huber et al. 2018
The 2014–16 West Africa epidemic devastated Guinea, Liberia, and Sierra Leone — three countries whose combined GDP was modest — through a combination of direct disease cost and, more importantly, behavioral aversion: economic activity stopped across agriculture, mining, and trade as fear spread faster than the virus. The broader social and economic burden, including non-Ebola deaths from disrupted health systems, has been estimated at ~$53 billion.
Correction, published September 20, 2026. An earlier version of this card described a "$2.2B cumulative GDP loss" for Guinea, Liberia and Sierra Leone through 2015. The $2.2 billion figure is the World Bank's October 2014 "Low Ebola" estimate for West Africa as a whole for 2014 alone; the same scenario adds $1.6 billion for 2015. The same error was corrected on the Ebola spoke on September 14, 2026 and had been carried here unchanged. Logged on the corrections page.
The key insight: fear of Ebola cost more than Ebola itself in the affected region.
Full Ebola economic analysis → · What US treatment cost per patient →
~$10.6B annual U.S. cost; ~$60.3B global societal cost
Norovirus is the leading cause of acute gastroenteritis in the U.S. — 19–21 million cases per year — yet it rarely makes headline news outside cruise-ship outbreaks. Its $10.6 billion annual U.S. economic burden is driven 89% by productivity losses (missed work, caregiving) rather than direct medical costs. Outbreaks cluster in cruise ships, schools, long-term care facilities, and restaurants, generating concentrated costs in specific industries.
Full norovirus economic analysis → · What one outbreak costs, by setting →
No authoritative aggregate estimate exists
Hantavirus pulmonary syndrome kills roughly 38% of confirmed U.S. cases and has no approved treatment — yet its economic burden has no aggregate estimate because annual case counts (typically in the single digits to low tens) are too small for standard cost-of-illness methodology. Per-case costs are catastrophic: ICU admission and ECMO support routinely run to hundreds of thousands of dollars. Cases concentrate among rural agricultural workers and Native American communities in western states.
The data gap is itself informative: rare, severe diseases without effective treatments attract insufficient research funding to produce the burden estimates that would justify more funding.
Full hantavirus economic analysis →